Citi analysts added Cytokinetics (CYTK) and HII (HII) to the firm’s 2025 North America Focus List while removing IntercontinentalExchange (ICE) and Coca-Cola (KO). The list features Citi’s “differentiated, high conviction, catalyst-driven calls across the region.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes
- Biotech Alert: Searches spiking for these stocks today
- Cytokinetics’ Aficamten Poised as Best-in-Class Cardiac Treatment with Favorable Risk-Benefit Profile
- Optimistic Buy Rating for Cytokinetics: Aficamten’s Market Potential Amidst Competition
- Cytokinetics: A Promising Investment with Aficamten’s Competitive Edge in HCM Treatment